Amicus Therapeutics - FOLD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 16.91%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$12.83
▼ -0.34 (-2.58%)

This chart shows the closing price for FOLD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amicus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FOLD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FOLD

Analyst Price Target is $15.00
▲ +16.91% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Amicus Therapeutics in the last 3 months. The average price target is $15.00, with a high forecast of $16.00 and a low forecast of $14.00. The average price target represents a 16.91% upside from the last price of $12.83.

This chart shows the closing price for FOLD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Amicus Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/7/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/5/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/3/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/4/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2023BTIG ResearchBoost TargetBuy$14.00 ➝ $16.00Low
11/8/2022Morgan StanleyBoost TargetEqual Weight$14.00 ➝ $15.00Low
9/9/2022Morgan StanleyInitiated CoverageEqual Weight$14.00Low
4/13/2022The Goldman Sachs GroupInitiated CoverageNeutral ➝ NeutralHigh
2/24/2022SVB LeerinkLower TargetOutperform$16.00 ➝ $14.00High
1/13/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$12.00 ➝ $16.00Low
1/13/2022Cantor FitzgeraldLower TargetOverweight$16.00 ➝ $15.00Medium
11/15/2021Stifel NicolausUpgradeHold ➝ Buy$12.00 ➝ $16.00High
9/30/2021SVB LeerinkLower TargetMarket Perform$13.00 ➝ $12.00High
9/30/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$17.11 ➝ $16.00High
7/19/2021BTIG ResearchInitiated CoverageBuy$15.00Medium
7/1/2021Chardan CapitalReiterated RatingNeutralMedium
7/1/2021Berenberg BankInitiated CoverageHold$14.00Medium
6/10/2021SVB LeerinkReiterated RatingHoldHigh
5/27/2021Needham & Company LLCInitiated CoverageHoldLow
5/20/2021UBS GroupInitiated CoverageBuy$16.00High
4/19/2021Cantor FitzgeraldUpgradeNeutral ➝ OverweightN/A
4/13/2021Cantor FitzgeraldUpgradeNeutral ➝ Overweight$17.00 ➝ $17.00High
3/22/2021SVB LeerinkLower TargetMarket Perform$15.00 ➝ $13.00N/A
3/8/2021Stifel NicolausInitiated CoverageHold$13.00N/A
3/3/2021Robert W. BairdReiterated RatingBuyHigh
3/1/2021Stifel NicolausInitiated CoverageHold$13.00 ➝ $13.00High
2/12/2021CitigroupLower Target$27.00 ➝ $16.00Low
2/12/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$30.00 ➝ $15.00Low
2/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$19.00Low
2/12/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$30.00 ➝ $17.00Low
12/28/2020Cantor FitzgeraldInitiated CoverageOverweight$30.00 ➝ $30.00N/A
12/14/2020SVB LeerinkBoost TargetPositive ➝ Outperform$24.00 ➝ $30.00High
12/10/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$20.00 ➝ $27.00Low
11/11/2020Berenberg BankInitiated CoverageBuy ➝ Hold$21.00High
11/6/2020Robert W. BairdBoost TargetOutperform$20.00 ➝ $25.00Medium
11/6/2020SVB LeerinkBoost TargetOutperform$19.00 ➝ $24.00Medium
10/19/2020CowenReiterated RatingBuy$31.00Medium
10/9/2020Cantor FitzgeraldReiterated RatingOverweightHigh
8/11/2020HC WainwrightReiterated RatingBuy$20.00High
8/11/2020CitigroupBoost TargetBuy$15.00 ➝ $20.00High
6/16/2020HC WainwrightReiterated RatingBuy$20.00Low
6/16/2020BTIG ResearchInitiated CoverageBuy$19.00Low
6/8/2020JPMorgan Chase & Co.Reiterated RatingBuyHigh
5/19/2020SVB LeerinkReiterated RatingOutperform ➝ Market Perform$19.00High
5/18/2020JPMorgan Chase & Co.Boost TargetOverweight$18.00 ➝ $21.00High
5/9/2020Chardan CapitalReiterated RatingHold$12.50High
3/5/2020Chardan CapitalReiterated RatingHold$12.50Medium
3/3/2020HC WainwrightReiterated RatingBuy$20.00Low
2/4/2020Cantor FitzgeraldReiterated RatingOverweight$19.00 ➝ $20.00High
1/9/2020Robert W. BairdReiterated RatingBuy$20.00High
1/9/2020HC WainwrightReiterated RatingBuy$20.00High
11/21/2019HC WainwrightReiterated RatingBuy$20.00Medium
11/12/2019HC WainwrightBoost TargetBuy$18.00 ➝ $20.00Low
10/17/2019Cantor FitzgeraldReiterated RatingOverweightMedium
10/14/2019HC WainwrightReiterated RatingBuy$18.00Low
10/10/2019CowenSet TargetBuy$31.00Low
8/1/2019CowenReiterated RatingBuy$31.00Low
8/1/2019HC WainwrightReiterated RatingBuy$18.00High
7/15/2019HC WainwrightSet TargetBuy$18.00High
7/2/2019HC WainwrightReiterated RatingBuy$18.00Medium
6/17/2019HC WainwrightInitiated CoverageBuy ➝ Buy$18.00High
6/5/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$20.00 ➝ $19.00Low
5/8/2019Cantor FitzgeraldSet TargetBuy$20.00Low
4/22/2019Robert W. BairdSet TargetBuy$20.00Low
4/5/2019Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$13.91Medium
2/26/2019Cantor FitzgeraldReiterated RatingBuy$20.00Medium
2/5/2019Cantor FitzgeraldReiterated RatingBuy$20.00Medium
1/29/2019Cantor FitzgeraldInitiated CoverageOverweight$20.00Medium
1/16/2019CitigroupUpgradeNeutral ➝ Buy$12.59Medium
12/17/2018GuggenheimInitiated CoverageBuy$18.00High
10/29/2018CitigroupInitiated CoverageNeutral ➝ Neutral$12.00High
10/12/2018CowenReiterated RatingBuy$31.00Low
10/12/2018Chardan CapitalReiterated RatingHold$15.00High
8/17/2018Chardan CapitalDowngradeBuy ➝ Neutral$18.00 ➝ $15.00Medium
5/8/2018CowenReiterated RatingBuy$22.00Medium
2/8/2018SVB LeerinkBoost TargetOutperform ➝ Outperform$20.00 ➝ $24.00High
2/7/2018Robert W. BairdSet TargetBuy$20.00High
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/3/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/2/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
9/1/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/1/2022
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/31/2022
  • 6 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
11/30/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/30/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/29/2023

Current Sentiment

  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Amicus Therapeutics logo
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.
Read More

Today's Range

Now: $12.83
Low: $12.79
High: $13.21

50 Day Range

MA: $12.15
Low: $10.85
High: $13.39

52 Week Range

Now: $12.83
Low: $5.91
High: $13.61

Volume

1,783,935 shs

Average Volume

2,029,668 shs

Market Capitalization

$3.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Amicus Therapeutics?

The following equities research analysts have issued reports on Amicus Therapeutics in the last twelve months: BTIG Research, Morgan Stanley, StockNews.com, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for FOLD.

What is the current price target for Amicus Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Amicus Therapeutics in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 16.9%. BTIG Research has the highest price target set, predicting FOLD will reach $16.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $14.00 for Amicus Therapeutics in the next year.
View the latest price targets for FOLD.

What is the current consensus analyst rating for Amicus Therapeutics?

Amicus Therapeutics currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FOLD will outperform the market and that investors should add to their positions of Amicus Therapeutics.
View the latest ratings for FOLD.

What other companies compete with Amicus Therapeutics?

How do I contact Amicus Therapeutics' investor relations team?

Amicus Therapeutics' physical mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company's listed phone number is (215) 921-7600 and its investor relations email address is [email protected] The official website for Amicus Therapeutics is www.amicusrx.com. Learn More about contacing Amicus Therapeutics investor relations.